Krish S. Krishnan - 09 Jul 2025 Form 4 Insider Report for Krystal Biotech, Inc. (KRYS)

Role
President and CEO, Director, 10%+ Owner
Signature
/s/ Krish S. Krishnan
Issuer symbol
KRYS
Transactions as of
09 Jul 2025
Net transactions value
-$2,122,835
Form type
4
Filing time
11 Jul 2025, 17:44:09 UTC
Previous filing
13 Mar 2025
Next filing
16 Jul 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Krishnan Krish S President and CEO, Director, 10%+ Owner C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH /s/ Krish S. Krishnan 11 Jul 2025 0001298709

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KRYS Common Stock Sale $30,014 -200 -0.01% $150.07 1,532,856 09 Jul 2025 Direct F1, F2
transaction KRYS Common Stock Sale $995,497 -6,627 -0.43% $150.22 1,526,229 10 Jul 2025 Direct F1, F3
transaction KRYS Common Stock Sale $45,416 -300 -0.02% $151.39 1,525,929 10 Jul 2025 Direct F1, F4
transaction KRYS Common Stock Sale $30,028 -200 -0.01% $150.14 1,463,511 09 Jul 2025 By Spouse F6, F7, F8
transaction KRYS Common Stock Sale $976,464 -6,500 -0.44% $150.23 1,457,011 10 Jul 2025 By Spouse F3, F6, F8
transaction KRYS Common Stock Sale $45,416 -300 -0.02% $151.39 1,456,711 10 Jul 2025 By Spouse F4, F6, F8
holding KRYS Common Stock 90,000 09 Jul 2025 By Krishnan Spousal Trust
holding KRYS Common Stock 50,000 09 Jul 2025 By Krishnan Family Trust F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sales reported were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person that started on September 12, 2024 and will terminate on September 13, 2025 .
F2 The transaction was executed in two trades of 100 shares each at $150 and $150.14, respectively. The price reported above reflects the average sale price.
F3 The transaction was executed in multiple trades ranging from $150.00 to $150.8500. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F4 The transaction was executed in three trades of 100 shares each at $151.350, $151.40, and $151.41, respectively. The price reported above reflects the average sale price.
F5 Directly beneficially owned by the Krishnan Family Trust. The Reporting Person and his spouse are each joint beneficial owners of the trust with joint voting and investment control.
F6 The sales reported were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person's spouse, Suma M. Krishnan, that started on September 12, 2024 and will terminate on September 13, 2025.
F7 The transaction was executed in multiple trades ranging from $150.1200 to $150.1600. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F8 Directly beneficially owned by Suma M. Krishnan, the spouse of the Reporting Person.